FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549	

STATEMENT	OF CHANGES	S IN BENEFICIAL	OWNERSHIP

OMB APPROVAL										
OMB Number:	3235-0287									
Estimated average burden										
hours per response:	0.5									

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Last)	na Alfo	APEUTICS REET MA	Middle)		3. Da 08/3	2. Issuer Name and Ticker or Trading Symbol TCR2 THERAPEUTICS INC. [TCRR] 3. Date of Earliest Transaction (Month/Day/Year) 08/30/2019 4. If Amendment, Date of Original Filed (Month/Day/Year)							Check X	call app Direc Office below (idual or	er (give title Other (specify below) Chief Medical Officer r Joint/Group Filing (Check Applicable of filed by One Reporting Person of filed by More than One Reporting				
9/				on-Deriva	tive 9	Secu	rities	Acr	nuirec	l. Die	snosed of	or B	enefic	ially	Own	ed			
Table I - Non-Deriva 1. Title of Security (Instr. 3) 2. Transactive (Month/Day) Common Stock ⁽¹⁾ 08/30/2 Common Stock ⁽³⁾ 02/28/2			2A. Deemed Execution Date, if any (Month/Day/Year)		3. Transa Code (8) Code	ction	4. Securities	Acquired (A) or (D) (Instr. 3, 4 and 5) (A) or (D) Price A \$12.75 ⁽²⁾ A \$10.1 ⁽⁴⁾		75 ⁽²⁾	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)		Fori (D)	m: Direct or Indirect nstr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)				
		Та	ble II								osed of,				Owne	d t			
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercis Price of Derivative Security		Execu if any	eemed ution Date,	4. Transa Code (8)	action	5. Nu of Deriv	mber vative rities ired r osed)	·	e Exer ation D h/Day/		7. Title Amou Securi Under Deriva Securi 3 and	e and nt of ities lying itive ity (Instr.	8. F Der Sec (Ins	Price of ivative curity str. 5)	9. Number derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	y	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

- 1. The reporting person is voluntarily reporting the acquisition of shares of the issuer's common stock pursuant to the issuer's 2018 Employee Stock Purchase Plan ("ESPP") for the ESPP purchase period of February 13, 2019 through August 30, 2019. This transaction is exempt under Rule 16b-3(c).
- 2. In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's common stock on February 13, 2019.
- 3. The reporting person is voluntarily reporting the acquisition of shares of the issuer's common stock pursuant to the ESPP for the ESPP purchase period of September 2, 2019 through February 28, 2020. This transaction is exempt under Rule 16b-3(c).
- 4. In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's common stock on February 28, 2020.

Remarks:

/s/ Margaret Siegel as Attorney-in-Fact

03/27/2020

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.